Sign Up Today and Learn More About Cognito Therapeutics Stock
Invest in or calculate the value of your shares in Cognito Therapeutics or other pre-IPO companies through EquityZen, part of Morgan Stanley.
Cognito Therapeutics Stock (COGT)
Cognito Therapeutics is a neurotechnology company that is developing disease-modifying treatments for CNS illnesses.
About Cognito Therapeutics Stock
Founded
2016
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Cognito Therapeutics Press Mentions
Stay in the know about the latest news on Cognito Therapeutics
Cognito’s sensory device shows potential to preserve brain wiring in early Alzheimer’s
longevity • Jul 15, 2026
AAIC26: Cognito sheds light on biological underpinnings of Alzheimer’s headset
medicaldevice-network • Jul 15, 2026
Cognito Therapeutics Presents Exploratory Biomarker Data at AAIC 2026 Supporting Coordinated Modulation of Lipid Transport and Myelination Pathways
biospace • Jul 13, 2026
Four Alzheimer’s companies to watch at AAIC 2026
longevity • Jul 07, 2026
Cognito’s wearable device boosts brain proteins linked to Alzheimer’s protection
longevity • Jun 24, 2026
Cognito Therapeutics Management
Leadership team at Cognito Therapeutics
President
Zach Malchano
VP, BD and Strategic Partnerships
Martin Williams
Join now and verify your accreditation status to gain access to:
- Cognito Therapeutics Current Valuation
- Cognito Therapeutics Stock Price
- Cognito Therapeutics Management
- Available deals in Cognito Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Cognito Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Cognito Therapeutics Revenue and Financials
- Cognito Therapeutics Highlights
- Cognito Therapeutics Business Model
- Cognito Therapeutics Risk Factors
- Cognito Therapeutics Research Report from SACRA Research
Trading Cognito Therapeutics Stock
How to invest in Cognito Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Cognito Therapeutics through EquityZen funds. These investments are made available by existing Cognito Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Cognito Therapeutics stock?
Shareholders can sell their Cognito Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 55K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
